Browse

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

The FDA has paused its public release of pharma rejection letters as the agency seeks to avoid litigation around releasing the often sensitive information. The pause follows a law firm in April

An outbreak of diarrhea-causing parasite has grown to more than 1,000 cases, making it one of the nation’s largest such outbreaks in years.